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Significance of ST-segment Elevations in
Posterior Chest Leads (V7 to V9) in Patients
With Acute Inferior Myocardial Infarction
We read with much interest the article by S. Matetzky et al. (1). It is a
valid study emphasizing the value of posterior chest lead (V7 to V9) in
early identification of patients with larger inferior myocardial infarc-
tion (IMI) exhibiting more benefit from effective thrombolysis.
We also performed 16 lead ECGs (12 leads, V7 V8 V9 and V4 R)
in a series of 66 first IMIs admitted within six hours of chest pain (2).
Like Matetzky et al. we observed significantly lower radionuclide left
ventricular ejection fraction, higher peak creatine kinase levels and
more frequent 12 lead-ECG pattern of posterior wall extension when
ST elevation was greater than 0.05 mV in lead V9. Unlike the authors
we did not observe any difference in the in-hospital clinical course. We
explained the observation by the fact that right ventricular infarction
(RVI) was significantly more frequent in our control group. In spite of
the important role of RVI in IMI (3), the authors did not record V4 R
and they did not discuss the possible influence of RVI on the prognosis
while right coronary artery was more frequently involved in their
control group (63% and 90%, p , 0.003).
They also did not discuss the balance of other early 12 lead-ECG
prognostic markers (4) among the groups, which could have influenced
the results.
We believe that independent prognostic value of posterior chest
leads (V7 to V9) in IMI has to be assessed in a multivariate analysis
combining initial 16 lead ECG variables and clinical predictors of
events before recommending its systematic use in IMI.
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Better Patency With SK Than With tPA?
We read with interest the comments of Peto and Collins. However, we
must disagree with the interpretation that the results in 13 patients
treated with SK at 6 h after pain onset are the sole basis for the main
claims about the findings of our study. In fact, rather than focusing on
small patient subsets, we chose to perform multivariate analysis of the
probability of early patency as a logistic function of the agent used, the
time to treatment and their potential interaction. Indeed, the results of
this analysis on the whole cohort of 481 patients identified a negative
effect of treatment on the patency probability for SK but not for
accelerated tPA. A similar negative correlation between the time from
symptom onset to treatment and the patency rate has been reported by
other investigators with other “non-fibrin-specific agents” than strep-
tokinase (1,2). Finally, our report was not intended nor presented as a
comparison of the clinical benefit of streptokinase versus accelerated
tPA, which has been the subject of intense discussion elsewhere (3),
but rather as a mechanistic analysis.
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